hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Early works and origins === The Fisher King first appears in Chrétien de Troyes's Perceval, the Story of the Grail in the late 12th century, but the character's roots may lie in Welsh mythology. He may be derived from the figure of Brân the Blessed in the Mabinogion. In the Second Branch of the Mabinogi, Bran has a cauldron that can resurrect the dead, albeit imperfectly: the revived dead can no longer speak. He gives this cauldron to the king of Ireland as a wedding gift for him and Bran's sister Branwen. Later, Bran wages war on the Irish and is wounded in the foot or leg, and the cauldron is destroyed. He asks his followers to sever his head and take it back to Britain, and his head continues talking and keeps them company on their trip. The group lands on the island of Gwales, where they spend 80 years in a castle of joy and abundance, but eventually they leave and bury Bran's head in London. This story has analogues in two other important Welsh texts: the Mabinogion tale "Culhwch and Olwen", in which King Arthur's men must travel to Ireland to retrieve a magical cauldron, and the poem The Spoils of Annwn, which speaks of a similar mystical cauldron sought by Arthur in the otherworldly land of Annwn.
== Classification == Honey is classified by its source (floral or not), and divisions are made according to the packaging and processing used. Regional honeys are also identified. In the US, honey is also graded on its color and optical density by USDA standards, graded on the Pfund scale, which ranges from 0 for "water white" honey to more than 114 for "dark amber" honey.
=== Phytochemicals === Bilberries contain diverse polyphenols, including tannins, organic acids, phenolic acids, and anthocyanins, specifically anthocyanidins as delphinidin and cyanidin glycosides. V. myrtillus bilberry pulp is red or purple, and V. uliginosum bog bilberry pulp is pale-coloured. The high anthocyanin content of V. myrtillus may cause staining of the fingers, lips, and tongue. The anthocyanin content of bilberries and bilberry juice may exceed the levels seen in blueberries and blueberry juice.
Ethanol is most commonly ingested by mouth, but other routes of administration are possible, such as inhalation, enema, or by intravenous injection. With oral administration, the ethanol is absorbed into the portal venous blood through the mucosa of the gastrointestinal tract, such as in the oral cavity, stomach, duodenum, and jejunum. The oral bioavailability of ethanol is quite high, with estimates ranging from 80% at a minimum to 94–96%. The ethanol molecule is small and uncharged, and easily crosses biological membranes by passive diffusion. The absorption rate of ethanol is typically modeled as a first-order kinetic process depending on the concentration gradient and specific membrane. The rate of absorption is fastest in the duodenum and jejunum, owing to the larger absorption surface area provided by the villi and microvilli of the small intestines. Gastric emptying is therefore an important consideration when estimating the overall rate of absorption in most scenarios; the presence of a meal in the stomach delays gastric emptying, and absorption of ethanol into the blood is consequently slower. Due to irregular gastric emptying patterns, the rate of absorption of ethanol is unpredictable, varying significantly even between drinking occasions. In experiments, aqueous ethanol solutions have been given intravenously or rectally to avoid this variation. The delay in ethanol absorption caused by food is similar regardless of whether food is consumed just before, at the same time, or just after ingestion of ethanol.
Sources: en.wikipedia.org
Applications of contact mechanics further extend into the micro- and nanotechnological realm. The original work in contact mechanics dates back to 1881 with the publication of the paper "On the contact of elastic solids" "Über die Berührung fester elastischer Körper" by Heinrich Hertz. Hertz attempted to understand how the optical properties of multiple, stacked lenses might change with the force holding them together. Hertzian contact stress refers to the localized stresses that develop as two curved surfaces come in contact and deform slightly under the imposed loads. This amount of deformation is dependent on the modulus of elasticity of the material in contact. It gives the contact stress as a function of the normal contact force, the radii of curvature of both bodies and the modulus of elasticity of both bodies. Hertzian contact stress forms the foundation for the equations for load bearing capabilities and fatigue life in bearings, gears, and any other bodies where two surfaces are in contact.
In 1916 Kuo-Ching Li, a Chinese-American engineer, founded Wah Chang Trading Corporation in New York State, but it was based in Albany. He developed it as an international tungsten ore and concentrate trading company, leading the company until his death in 1961. He served as president until 1960 and then board chairman. The U.S. Bureau of Mines established Albany Research Center (ARC) on the former Albany College campus in 1942, focusing on the development of new metallurgical processes. First known as the Northwest Electro-development Facility, the site eventually produced titanium and zirconium, spearheaded by William Justin Kroll whom the bureau hired in 1945. The first zirconium strip was rolled out there in August 1946. In 1951, William Kroll joined the faculty of Oregon State College, ten miles away in Corvallis. The ARC fostered the growth of a new rare metals industry in Albany, led by internationally recognized companies such as the Oregon Metallurgical Company, Oremet, and Wah Chang. In the 1970s, Albany attempted to extend its city limits to include a zirconium processing plant of Wah Chang Corporation in order to increase its industrial tax base. Wah Chang responded in 1974 by sponsoring a vote to incorporate the desired properties as Millersburg. When the Bureau of Mines closed in 1996, the ARC was transferred to the United States Department of Energy's Office of Fossil Energy. In 2005 the facility became part of the National Energy Technology Laboratory.
== Derivation == The HOMA authors used data from physiological studies to develop mathematical equations describing glucose regulation as a feedback loop. They published computer software that solves the equations, so that insulin resistance and β-cell function can be estimated from fasting glucose and insulin levels. They also published an equation (see below) that gave approximately the same answers as an early version of the computer software. The computer model has since been improved to a HOMA2 model to better reflect human physiology and recalibrated to modern insulin assays. In this updated version it is possible to determine insulin sensitivity and β-cell function from paired fasting plasma glucose and radioimmunoassay insulin, specific insulin, or C-peptide concentrations. The authors recommend the computer software be used wherever possible.
Sources: en.wikipedia.org
Zinc Fact Sheet from the U.S. National Institutes of Health History & Etymology of Zinc Statistics and Information from the U.S. Geological Survey Archived October 8, 2011, at the Wayback Machine Reducing Agents > Zinc American Zinc Association Information about the uses and properties of zinc. ISZB International Society for Zinc Biology, founded in 2008. An international, nonprofit organization bringing together scientists working on the biological actions of zinc. Zinc-UK Founded in 2010 to bring together scientists in the United Kingdom working on zinc. Zinc at The Periodic Table of Videos (University of Nottingham) ZincBind – a database of biological zinc binding sites.
== Further reading == Buzuev, Vladimir; Gorodnov, Vladimir (1987). What Is Marxism–Leninism?. Moscow: Progress Publishers. "Marxism–Leninism". Encyclopedia of Marxism. Marxists Internet Archive. Retrieved 31 December 2020. Kuusinen, Otto Will (1963). Fundamentals of Marxism–Leninism. Translated by Dutt, Clemens (2nd rev. ed.). Moscow: Foreign Languages Publishing House. OCLC 1091006. OL 5975949M. Kuusinen, Otto Will (2022). Fundamentals of Marxism–Leninism. Translated by Dutt, Clemens. United States: Marx Engels Lenin Press. ISBN 979-8-8114-4663-6. Sheptulin, Alexander. Marxist-Leninist Philosophy. Moscow: Progress Publishers. OL 2170371W. Stalin, Joseph (1924). "The Foundations of Leninism". Works. Vol. 6. Moscow: Foreign Languages Publishing House. pp. 71–196. Spirkin, Alexander (1990). Fundamentals of Philosophy. Translated by Syrovatkin, Sergei. Moscow: Progress Publishers. ISBN 978-5-0100-2582-3.
== Limitations == One of the main limitations of ITC is that it is prone to allowing only moderate binding conformations to be detected, making it less effective for detecting very weak or extremely tight binding events. Hence, it may struggle to provide accurate thermodynamic parameters for slow kinetic processes with long time constants, as these interactions may be masked by baseline noise and variability. On the other hand, high-affinity interactions can be challenging to measure if they take several minutes or longer to fully develop, or if the measured signal depends on the reaction enthalpy. When the binding enthalpy is close to zero, ITC may fail to generate meaningful interaction data, instead producing a series of small, uniform peaks that result in flat and uninformative thermograms. ITC is also susceptible to interference from unrelated heat signals, making it difficult to isolate and interpret the heat changes associated with the interaction of interest. Other limitations include solubility constraints, challenges in accurately determining protein concentration and the need to prepare the ligand in the same solution conditions as the protein for reliable measurements.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.